Call Us: 1.800.873.5297

By

TVM Update: $5.7 Million Jury Verdict Against Johnson & Johnson in California Transvaginal Mesh Case

According to Reuters, yet another jury has returned a multi-million dollar award against Johnson & Johnson in a vaginal mesh lawsuit. In the latest of a series of trials, a California state jury sitting in Kern County awarded a $5.7 million verdict against Johnson & Johnson and its subsidiary Ethicon for complications with Ethicon’s Gynecare TVT […]

By

Xarelto Expanded Use Denied Again by FDA

According to Reuters, the FDA once again declined to approve wider uses of the prescription drug Xarelto® (Rivaroxaban) late last month. Currently, the drug’s biggest approved use is to prevent blood clots and strokes in patients with an irregular heartbeat called atrial fibrillation. Recently, the drug’s co-marketers—Bayer AG and Johnson & Johnson—tried to expand the drug’s […]

By

Law360 Reports GM Settles Second Faulty Ignition Switch Lawsuit; Documents Indicate Cover Up

According to Law360, millions of documents have allegedly been produced in a Georgia lawsuit showing General Motors engaged in a “massive cover up” to hide a deadly ignition switch defect. Brooke Melton was killed on her 29th birthday in 2010 when her car lost power and slid into an oncoming car. An expert engineer looked […]

By

Johnson & Johnson Subsidiary McNeil PPC Inc. Pleads Guilty to Selling Children’s Medicine Containing Metal Particles

According to Law360, a unit of the healthcare giant Johnson & Johnson pleaded guilty Tuesday to a federal criminal charge for selling infants’ and children’s medicine containing metal particles. The subsidiary—McNeil PPC Inc.—must pay a $20 million criminal fine and forfeit $5 million. Unsealed court documents say metal particles, including nickel, iron, and chromium, were […]

By

Risperdal: $2.5 Million Verdict for Plaintiff in Philadelphia State Court

Philadelphia Daily News reports that a Philadelphia jury has awarded a 20 year old autistic man, Austin Pledger, $2.5 million after he developed size 46 DD breasts (a condition referred to as gynecomastia) as a young teenager after using the antipsychotic drug Risperdal. In particular, the jury found that the manufacturer, Johnson & Johnson, failed […]

By

FDA Requires New Labeling Change for Testosterone Drugs Regarding Increased Risk of Heart Attack and Stroke

On March 3, 2015, the Food and Drug Administration (FDA) issued a Safety Announcement cautioning that testosterone products are approved only for men who have low testosterone levels caused by certain medical conditions, rather than due to aging. The FDA also required manufacturers of testosterone drugs to clarify the approved uses of these medications and […]

By

Actos® Lawsuit Update: Philadelphia Jury Returns $2.3 Million Verdict In Favor of the Plaintiff

Bloomberg reports that a Philadelphia jury has returned a $2.3 million verdict in favor of the plaintiff after finding that the diabetes drug Actos® had been a significant cause of the plaintiff’s bladder cancer. The case is Kristufek v. Takeda Pharmaceuticals America Inc., Philadelphia Court of Common Pleas, Case ID 120702275. The jury also found that […]

By

Research Reveals Big Pharmaceutical Companies Spending More on Sales and Marketing than Research and Development

According to the Washington Post, a study conducted by the healthcare research firm GlobalData revealed that nine out of ten big pharmaceutical companies are spending more on sales and marketing than research and development (R&D). Johnson & Johnson, the biggest spender, expended roughly $17.5 billion dollars on sales and marketing in 2013, compared with $8.2 billion […]

By

AstraZeneca Pays $7.9 Million for Alleged Violations of Anti-Kickback Laws

The Wall Street Journal reports that the drug manufacturer, AstraZeneca, will pay $7.9 million to the federal government over allegations that the manufacturer violated anti-kickback laws and attempted to defraud the federal, state, and local U.S. governments. The drugmaker is accused of paying kickbacks to a large Pharmacy Benefits Manager in exchange for a guarantee that […]

By

Xarelto® Lawsuit Update: Roger C. Denton of Schlichter, Bogard & Denton, LLP Appointed to Plaintiffs’ Steering Committee

On February 9, 2015 the Honorable Eldon Fallon, sitting in the U.S. District Court for the Eastern District of Louisiana, appointed Roger C. Denton of Schlichter, Bogard & Denton, LLP to the Plaintiffs’ Steering Committee (PSC) in the national Xarelto® Multidistrict Litigation (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:14-md-02592, MDL 2592, Pretrial […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.